Nurosene's CSO And Director Of Bioinformatics Receives 'Highly Cited Paper' Award For AI-Based Alzheimer's Research Findings

The research demonstrates that even within a relatively small study sample, Nurosene's powerful AI platform can accurately stratify patient subpopulations. Additionally, the research identified that AD is not one disease but a heterogeneously complex disorder made up of many diseases. This represents a significant breakthrough in the understanding of AD. Nurosene's recent partnership with Cyclica will benefit from these insights as we uncover new ways to treat Alzheimer's disease and early dementia.

"I am honoured that so many of my peers saw value in the research, and I am gratified that the effectiveness and power in our novel approach to AI is being recognized. I am excited by the way we can commercialise these insights with our partners in the neurodegeneration space."

~ Dr. Joseph Geraci, Nurosene's Chief Scientific Officer

Nurosene's powerful technology represents a new paradigm of machine learning, moving from machines that rely on human-generated labels to causal machine learning that teaches us about disease and how to best treat individual patients. This new approach focuses on learning about what is causing a disease and its various forms. The technology allows physicians and scientists to have a deep connection with the models generated so that their expertise is optimised. Nurosene's AI platform thrives with smaller data sets and heterogeneous patient populations like cancer, neurodegenerative diseases, inflammation, psychiatric disorders, and ageing. In addition to biomarker identification, this technology is used to accelerate new drug discovery and to prevent clinical trial failure via precise patient stratification for drug efficacy, adverse events, and placebo response.

Exploration of Medicine, a peer-reviewed, open access online journal, publishes articles that provide substantial and novel insights into medicine. Their award was based on quality, number of citations, and downloads. The paper, Using machine intelligence to uncover Alzheimer's disease progression heterogeneity was published in December of 2020 and was one of six articles selected.

__________________________________

[1] https://www.mordorintelligence.com/industry-reports/alzheimers-diagnosis-and-drugs-market

About Nurosene

Nurosene is a healthtech company focused on delivering innovative AI-based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.

For more information, visit www.nurosene.com.

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, Nurosene's research activities in partnership with Cyclica Inc., potential results, uses and the impact of the research including the identification of treatments and drugs, the importance of the research, possible enhancements to our technology and other initiatives related thereto.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2022/08/c9811.html